Request Your Free Analyst Report Now:

"Airfinity's latest COVID-19 Vaccine Revenue Forecast 2022"

Airfinity downgrades its global COVID-19 vaccine revenue forecast as demand falls and inventory increases

Analysis of vaccine production, deliveries, supply deals and doses administered shows demand is falling and with it vaccine sales.

Vaccination rates around the world have rapidly dropped since the start of 2022. Airfinity forecasts annual demand to be 6 billion doses this year, falling to between 2-4 billion in 2023 and beyond.

As a result, Airfinity has downgraded its global sales forecast for COVID-19 vaccines this year from $80.8bn to $64.1bn.

Download the report today.

Offered Free by: Airfinity Ltd
See All Resources from: Airfinity Ltd